Australia was promised a world-class vaccine program. But instead of a rollout, we got an eekout.
The amount of risk from overseas arrivals depends not just on Australia's vaccination rates, but also on the particular circumstances of the country from which people are travelling.
Hospital staff in Lagos, Nigeria, administer the AstraZeneca vaccine.
AP Photo/Sunday Alamba
India and South Africa are pressing the World Trade Organization to waive patent rights to help ramp up vaccine production. There's a better solution.
Generally speaking, fault can only be proven when the doctor has acted outside of the professional standard of care.
COVAX, the global vaccine distribution initiative, is well behind its goal of delivering 2 billion doses this year due to under-investment, vaccine nationalism and export restrictions.
The challenge now is to address the understandable concerns and prevent them from contaminating the broader public dialogue on COVID-19 vaccination.
The AstraZeneca vaccine was 70 per cent effective against symptomatic COVID-19 infection in a large multinational study, and recently reported 76 per cent overall efficacy against symptomatic COVID-19 in another large study done primarily in the United States.
THE CANADIAN PRESS/John Woods
With changing recommendations about AstraZeneca's COVID-19 vaccine making headlines, many people have questions about its use.
This week's unwelcome medical advice about the AstraZeneca vaccine is the latest setback to the rollout and the Morrison government.
This shift in focus away from AstraZeneca to the Pfizer vaccine has serious impacts on the timing of the rollout and public confidence in the AstraZeneca vaccine.
A healthcare worker administers an Oxford/AstraZeneca COVID-19 vaccine to her colleague at Mutuini Hospital in Nairobi. Kenya on March 3, 2021.
Photo by Dennis Sigwe/SOPA Images/LightRocket via Getty Images
Kenya grapples with two major challenges in the vaccination rollout: access to sufficient doses in light of the global shortage; and vaccine hesitancy.
The vaccine rollout was thrown into fresh uncertainty on Thursday night after the government received medical advice against using the AstraZeneca vaccine for people under 50 because of the very small risk of blood clots.
Luong Thai Linh/AAP
Stephen Duckett on what’s wrong with the rollout.
Michelle Grattan discusses the vaccine rollout with Stephen Duckett.
Charlie J Ercilla / Alamy Stock Photo
Good news for children and young people, bad news for Johnson & Johnson.
These mistakes have been mainly caused by our leaders giving priority to a good political story over good policy.
Who jumped the queue?
J. J. Guillen/EPA
The UK says its contract is better – it simply put tougher penalty clauses in place.
The AstraZeneca vaccine is already in use in many places.
AP Photo/Christophe Ena
AstraZeneca just announced results from its US-based trial. It found the vaccine to be 79% effective and safe for use, despite recent concerns around reports of blood clots.
fabrus/Alamy Stock Photo
Underlying medicines 'do no harm' principle is a deeper claim that it is worse to do harm than to allow harm to happen.
Supply chain issues can be addressed – but the issues with the AstraZeneca vaccine are political, too.
The AstraZeneca vaccine has been investigated and found safe, but will countries be able to get enough of it?
Marc Bruxelle/Alamy Stock Photo
The European Medicines Agency has said the Oxford/AstraZeneca vaccine is not associated with an increased overall risk of developing blood clots.
It's not too late for Australia to repair our vaccine strategy, though we will never make up for the months lost.